Dashboard
Manage Tickers

MRUSMerus N.V.

Nasdaq merus.nl


$ 50.99 $ 0.51 (1.01 %)    

Friday, 30-Aug-2024 15:59:47 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 476.00 $ 5.61 (1.19 %)
DIA $ 416.44 $ 2.30 (0.56 %)
SPY $ 563.62 $ 5.33 (0.95 %)
TLT $ 96.60 $ -1.04 (-1.07 %)
GLD $ 231.30 $ -1.66 (-0.71 %)
$ 50.99
$ 50.98 x 100
-- x --
-- - --
$ 19.81 - $ 61.61
378,905
na
3.48B
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-28-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-02-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-16-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-16-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

foundation-medicine-and-merus-collaborate-on-rna-platform-for-targeting-neuregulin-1-fusion-cancers
Foundation Medicine and Merus Collaborate ...
08/28/2024 11:13:21

Foundation Medicine, Inc. today announced a collaboration to develop Foundation Medicine's RNA platform as a companion diag...

needham-maintains-buy-on-merus-lowers-price-target-to-85
Needham Maintains Buy on Merus, Lowers Pri...
08/05/2024 09:31:29

Needham analyst Ami Fadia maintains Merus (NASDAQ:MRUS) with a Buy and lowers the price target from $92 to $85.

merus-q2-eps-081-misses-076-estimate-sales-733m-miss-844m-estimate
Merus Q2 EPS $(0.81) Misses $(0.76) Estima...
08/01/2024 21:17:10

Merus (NASDAQ:MRUS) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.76) by 6....

canaccord-genuity-maintains-buy-on-merus-maintains-67-price-target
Canaccord Genuity Maintains Buy on Merus, ...
07/25/2024 13:15:05

Canaccord Genuity analyst John Newman maintains Merus (NASDAQ:MRUS) with a Buy and maintains $67 price target.

merus-announced-that-the-first-patient-has-been-dosed-in-the-companys-phase-3-trial-evaluating-the-efficacy-and-safety-of-petosemtamab-in-previously-treated-23l-patients
Merus Announced That The First Patient Has...
07/24/2024 11:08:46

merus-nv-doses-first-patient-in-phase-2-trial-of-petosemtamab-for-second-line-metastatic-colorectal-cancer-biclonics-therapy-targets-egfr-and-lgr5
Merus N.V. Doses First Patient In Phase 2 ...
07/08/2024 12:01:01

needham-reiterates-buy-on-merus-maintains-92-price-target
Needham Reiterates Buy on Merus, Maintains...
06/28/2024 09:41:27

Needham analyst Ami Fadia reiterates Merus (NASDAQ:MRUS) with a Buy and maintains $92 price target.

citigroup-maintains-buy-on-merus-raises-price-target-to-93
Citigroup Maintains Buy on Merus, Raises P...
06/26/2024 16:37:45

Citigroup analyst Yigal Nochomovitz maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $70 to $93.

b-of-a-securities-maintains-buy-on-merus-maintains-76-price-target
B of A Securities Maintains Buy on Merus, ...
06/25/2024 17:18:05

B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:MRUS) with a Buy and maintains $76 price target.

stifel-maintains-buy-on-merus-raises-price-target-to-99
Stifel Maintains Buy on Merus, Raises Pric...
06/17/2024 11:48:41

Stifel analyst Bradley Canino maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $90 to $99.

b-of-a-securities-maintains-buy-on-merus-lowers-price-target-to-76
B of A Securities Maintains Buy on Merus, ...
06/05/2024 12:12:05

B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:MRUS) with a Buy and lowers the price target from $80 to $76.

bmo-capital-maintains-outperform-on-merus-raises-price-target-to-91
BMO Capital Maintains Outperform on Merus,...
06/04/2024 14:03:32

BMO Capital analyst Etzer Darout maintains Merus (NASDAQ:MRUS) with a Outperform and raises the price target from $84 to $91.

truist-securities-maintains-buy-on-merus-raises-price-target-to-88
Truist Securities Maintains Buy on Merus, ...
06/04/2024 12:52:38

Truist Securities analyst Asthika Goonewardene maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $69...

merus-mcla-129-demonstrates-single-agent-efficiency-in-metex14-nsclc-in-poster-presentation-at-asco-2024
Merus' MCLA-129 Demonstrates Single-Agent ...
06/03/2024 18:31:47

Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length...

merus-presented-interim-data-on-mcla-145-monotherapy-and-in-combination-with-pembrolizumab-at-asco-2024
Merus Presented Interim Data On MCLA-145 M...
06/02/2024 18:27:58

Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length...

reported-earlier-merus-prices-upsized-public-offering-of-755m-common-shares-at-53share
Reported Earlier, Merus Prices Upsized Pub...
05/30/2024 06:15:18

The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses a...

b-of-a-securities-maintains-buy-on-merus-raises-price-target-to-80
B of A Securities Maintains Buy on Merus, ...
05/29/2024 12:07:16

B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $61 to $80.

hc-wainwright--co-maintains-buy-on-merus-raises-price-target-to-85
HC Wainwright & Co. Maintains Buy on Merus...
05/29/2024 10:26:44

HC Wainwright & Co. analyst Andrew Fein maintains Merus (NASDAQ:MRUS) with a Buy and raises the price target from $65 to...

merus-announces-300m-proposed-public-offering
Merus Announces $300M Proposed Public Offe...
05/28/2024 20:02:01

why-applied-dna-sciences-shares-are-trading-lower-by-around-68-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Applied DNA Sciences Shares Are Tradin...
05/28/2024 17:24:16

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION